GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review

Laurence Aoun; Shaza Almardini; Fares Saliba; Fadi Haddadin; Omar Mourad; Jennifer Jdaidani; Zeina Morcos; Ibrahim Al Saidi; Elie Bou Sanayeh; Saliba Saliba; Michel Almardini; Julie Zaidan

doi:10.1016/j.jcte.2024.100333

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review

J Clin Transl Endocrinol. 2024 Feb 29:35:100333. doi: 10.1016/j.jcte.2024.100333. eCollection 2024 Mar.

Affiliations

¹ Department of Internal Medicine, Staten Island University Hospital, United States.
² Department of Physiology, Mcgill University, United States.
³ Faculty of Medicine, American University of Beirut Medical Center, Lebanon.
⁴ Endocrinology, Diabetes and Metabolism, Staten Island University Hospital, United States.

Abstract

Objective: Systematically review evidence on using GLP-1RAs for reducing BEB in BED and BN.

Methods: Comprehensive literature search (PubMed and Google Scholar) conducted for studies evaluating GLP-1Ras for BEB. Extracted data on study characteristics, efficacy, and safety.

Results: Studies show that GLP-1RAs (liraglutide and dulaglutide) reduce BE frequency and comorbidities in addition to favorable psychiatric side effect profile compared to current options. However, large-scale, blinded placebo-controlled trials are lacking.

Conclusion: Early findings suggest promising effects of GLP-1RAs on BEB. However, rigorous clinical trials are needed to firmly establish efficacy, dosing, safety, and comparative effectiveness before considering GLP-1RAs a viable novel approach.

Keywords: BED; Binge Eating Disorder; Bulimia nervosa; Dulaglutide; Eating Disorders; Glucagon-like peptide-1 receptor agonist; Liraglutide; Semaglutide.

Publication types

Review